TMCnet - World's Largest Communications and Technology Community



Research and Markets: Graft vs Host Disease Hem/Onc Thought Leader Panel #35 2013-07 GVHD
[February 21, 2014]

Research and Markets: Graft vs Host Disease Hem/Onc Thought Leader Panel #35 2013-07 GVHD

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Graft vs Host Disease Hem/Onc Thought Leader Panel #35 2013-07 GVHD" report to their offering.

Reducing immunosuppression without allowing tumor regrowth, i.e. trying to prevent graft vs host disease without abrogating the graft vs leukemia effect, is the Holy Grail of transplant biology.

Like the Grail, really effective ways of achieving this goal haven't been demonstrated in completed randomized trials. But there are, finally, plausible hypotheses to explain the underlying pathophysiology of GVHD, and there are therapeutic approaches in the clinic that may capitalize on this new understanding.

The Hem/Onc Thought Leader Panel (TLP) #35 summarizes the perspectives of six renowned US and European Thought Leaders who specialize in the treatment of graft-vs- host disease. The Ad Board was run in June/July 2013.

The Panel discussed the following topics / drugs:

Market Size (US, Annual)

- GVHD Risk Factors

Prevention of GVHD in Allogeneic Transplant Patients

- Metrics for Prevention Trials

- Myeloablative vs Non-Myeloablative Transplants

Acute GVHD

- Treatment of Acute GVHD (Steroid Responsive)

- Protocols for Steroid-Responsive or Steroid-Incomplete Responder GVHD

- Treatment of Acute GVHD (Steroid Refractory)

Chronic GVHD

- Metrics for Chronic GVHD Trials

- Predictive Biomarkers

Therapeutic Approaches

- Treg

- IL2: Low Dose IL2 (Dana Farber)

-- cyclophosphamide


- CD20: Rituxan / MabThera; rituximab (Roche)

-- BTK (Bruton's Tyrosine Kinase) Ibrutinib (Pharmacyclics / Janssen)

- CD19 CARS (Chimeric Antigen Receptor)

Mesenchymal Stem Cells

- Prochymal; remestemcel-L (Osiris)

- MultiStem (Athersys / Pfizer)


- maraviroc (Selzentry) Pfizer

Proteasome Inhibition

- Velcade (bortezomib; Takeda)

T Cell Depletion

- anti-Thymoglobulin

- rabbit ATG (News - Alert); Fresenius

Gene Modified Donor T-Cells

Suicide Genes

- BPX-501; Bellicum

- TK008 (Molmed)


- CliniMACS (CD34 selection; Miltenyi Biotec)


- Extracorporeal photopheresis

- cyclophosphamide


- BEGEDINA® (Adienne)


- Zolinza (vorinostat; Merck)

For more information visit

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy